Norsk forening for medisinsk mikrobiologi


Publikasjoner i 1999

  1. Aaberge, I. S. 1999. Pneumococcal vaccine in the elderly: the Norwegian experience. Drugs Aging 15 Suppl 1:37-41.

  2. Aandahl, E. M., P. Aukrust, F. Müller, V. Hansson, K. Tasken, and S. S. Frøland. 1999. Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS 13:F109-F114.

  3. Alseth, I., L. Eide, M. Pirovano, T. Rognes, E. Seeberg, and M. Bjørås. 1999. The Saccharomyces cerevisiae homologues of endonuclease III from Escherichia coli, Ntg1 and Ntg2, are both required for efficient repair of spontaneous and induced oxidative DNA damage in yeast. Mol.Cell Biol. 19:3779-3787.

  4. Andersen, B. M., K. Bergh, M. Steinbakk, G. Syversen, B. Magnaes, H. Dalen, and J. N. Bruun. 1999. A Norwegian nosocomial outbreak of methicillin-resistant Staphylococcus aureus resistant to fusidic acid and susceptible to other antistaphylococcal agents. J.Hosp.Infect. 41:123-132. 

  5. Aukrust, P., and F. Müller. 1999. Glutathione redox disturbances in human immunodeficiency virus infection: immunologic and therapeutic consequences. Nutrition. 1999 Feb;15(2):165-167.

  6. Aukrust, P., E. M. Aandahl, B. S. Skalhegg, I. Nordøy, V. Hansson, K. Tasken, S. S. Frøland, and F. Müller. 1999. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J. Immunol. 162:1178-1185.

  7. Aukrust, P., C. J. Haug, T. Ueland, E. Lien, F. Müller, T. Espevik, J. Bollerslev, and S. S. Frøland. 1999. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J. Clin. Endocrinol. Metab. 84:145-150.

  8. Aukrust, P., F. Müller, E. Lien, I. Nordøy, N. B. Liabakk, D. Kvale, T. Espevik, and S. S. Frøland. 1999. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J. Infect. Dis. 179:74-82.

  9. Aukrust, P., F. Müller, M. Svenson, I. Nordøy, K. Bendtzen, and S. S. Frøland. 1999. Administration of intravenous immunoglobulin (IVIG) in vivo--down- regulatory effects on the IL-1 system. Clin. Exp. Immunol. 115:136-143.

  10. Aukrust P, F. Müller, T. Ueland, T. Berget, E. Aaser, A. Brunsvig, N.O. Solum, K. Forfang, S.S. Frøland, and L. Gullestad. 1999. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100(6):614-620.

  11. Aukrust P, T. Ueland, E. Lien, K. Bendtzen, F. Müller, A.K. Andreassen, I. Nordøy, H. Aass, T. Espevik, S. Simonsen, S.S. Frøland, and L. Gullestad. 1999. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 83(3):376-382.

  12. Bærheim, A., A. Digranes, and S. Hunskaar. 1999. Are resistance patterns in uropathogens published by microbiological laboratories valid for general practice? APMIS 107:676-680.

  13. Bærheim, A., A. Digranes, and S. Hunskaar. 1999. Equal symptomatic outcome after antibacterial treatment of acute lower urinary tract infection and the acute urethral syndrome in adult women. Scand.J.Prim.Health Care 17:170-173.

  14. Bell, H., K. Hellum, S. Harthug, B. Myrvang, S. Ritland, A. Mæland, L. B. von der, K. Bjøro, K. Skaug, B. G. Gutigard, N. Raknerud, and P. Simmonds. 1999. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group. Scand.J.Gastroenterol. 34:194-198.

  15. Brorson, O., and S. H. Brorson. 1999. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to metronidazole. APMIS 107:566-576.

  16. Dahl, K. H., G. S. Simonsen, Ø. Olsvik, and A. Sundsfjord. 1999. Heterogeneity in the vanB gene cluster of genomically diverse clinical strains of vancomycin-resistant enterococci. Antimicrob.Agents Chemother. 43:1105-1110.

  17. Dahlgren, A., C. Glogard, M. Gammelsæther, A. J. Aasen, J. Klaveness, B. P. Berdal, and T. Bergan. 1999. Organobismuth compounds: activity against Helicobacter pylori. Scand.J.Gastroenterol. 34:135-137.

  18. Dyrhol-Riise, A. M., P. Voltersvik, J. Olofsson, and B. Åsjø. 1999. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection. AIDS 13:2365-2376.

  19. Eggesbø, H. B., S. Ringertz, O. C. Haanæs, S. Dolvik, A. Erichsen, M. Stiris, and F. Kolmannskog. 1999. CT and MR imaging of the paranasal sinuses in cystic fibrosis. Correlation with microbiological and histopathological results. Acta Radiol. 40:154-162.

  20. Gautun, H. S., T. Bergan, and P. H. Carlsen. 1999. Preparation and antimicrobial studies of acyclic sulfamates. Acta Chem.Scand. 53:446-452.

  21. Grinde, B., I. Olsaker, and E. Tjøtta. 1999. CAG repeats in various organisms studied by Southern blot analysis. Biochem.Genet. 37:109-117.

  22. Hansen, S., K. K. Melby, S. Aase, E. Jellum, and S. E. Vollset. 1999. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control study. Scand.J.Gastroenterol. 34:353-360.

  23. Hjelde, A., A.O. Brubakk, K. Bergh, V. Videm, and A-L. Ustad. 1999.  The effect of anti-C5a antibody on blood-lung and blood-brain barrier in rabbits after decompresssion. Undersea and Hyperbaric Medicine, Undersea Hyperb. Med. 26(4):249-56.

  24. Holberg-Petersen, M., M. Steinbakk, K. J. Figenschau, E. Jantzen, J. Eng, and K. K. Melby. 1999. Identification of clinical isolates of Mycobacterium spp. by sequence analysis of the 16S ribosomal RNA gene. Experience from a clinical laboratory. APMIS 107:231-239.

  25. Hvalbye, B. K., I. S. Aaberge, M. Løvik, and B. Haneberg. 1999. Intranasal immunization with heat-inactivated Streptococcus pneu moniae protects mice against systemic pneumococcal infection. Infect.Immun. 67:4320-4325.

  26. Jenkins A., Y. Tveten, and B.E. Kristiansen. 1999.  Carriage of meningococci in contacts of patients with meningococcal disease (letter). BMJ 318:66.

  27. Jensenius, M., G. Hasle, A. Z. Henriksen, S. Vene, D. Raoult, A. L. Bruu, and B. Myrvang. 1999. African tick-bite fever imported into Norway: presentation of 8 cases. Scand.J.Infect.Dis. 31:131-133.

  28. Kristiansen B.E., and T. Flægstad. 1999. Guidelines for the diagosis and treatment of meningococcal meningitis. Disease Management Health Outcomes 5:73-81.

  29. Kvale, D., P. Aukrust, K. Osnes, F. Müller, and S. S. Frøland. 1999. CD4+ and CD8+ lymphocytes and HIV RNA in HIV infection: high baseline counts and in particular rapid decrease of CD8+ lymphocytes predict AIDS. AIDS 13:195-201.

  30. Kvam, A. I., L. Bevanger, and J. A. Mæland. 1999. Properties and distribution of the putative R3 protein of Streptococcus agalactiae. APMIS 107:869-874.

  31. Leegaard, T. M., E. Vik, D. A. Caugant, L. O. Frøholm, and E. A. Høiby. 1999. Low occurrence of antibiotic resistance in Escherichia coli and staphylococci isolated from blood cultures in two Norwegian hospitals in 1991-92 and 1995-96. APMIS 107:1060-1068.

  32. Lehmann, A. K., A. Halstensen, I. S. Aaberge, J. Holst, T. E. Michaelsen, S. Sørnes, L. M. Wetzler, and H. Guttormsen. 1999. Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB. Infect.Immun. 67 :2552-2560.

  33. Mollnes, T. E., H-J. Haga, J.G. Brun, E.W.  Nielsen, A. Sjøholm, G. Stufeldt, U. Mårtensson, K. Bergh, and O.P. Rekvig.  1999. Complement activation in patients with systemic lupus erythematosus without nephritis. Rheumatology 38: 933-940.

  34. Mæland, J. A., L. Bevanger, G. Iversen, and R. V. Lyng. 1999. bca, beta gene, and gene product divergency in reference and prototype strains of streptococcus agalactiae. Clin.Diagn.Lab Immunol. 6:986-988.

  35. Melby, K. K., T. K. Kvien, and A. Glennås. 1999. Helicobacter pylori--a trigger of reactive arthritis? Infection 27:252-255.

  36. Mustafa, T., S. Phyu, R. Nilsen, G. Bjune, and R. Jonsson. 1999. Increased expression of Fas ligand on Mycobacterium tuberculosis infected macrophages: a potential novel mechanism of immune evasion by Mycobacterium tuberculosis? Inflammation 23 :507-521.

  37. Mustafa, T., S. Phyu, R. Nilsen, R. Jonsson, and G. Bjune. 1999. A mouse model for slowly progressive primary tuberculosis. Scand.J.Immunol. 50:127-136.

  38. Nordøy, I., F. Müller, K. P. Nordal, H. Rollag, E. Lien, P. Aukrust, and S. S. Frøland. 1999. Immunologic parameters as predictive factors of cytomegalovirus disease in renal allograft recipients. J.Infect.Dis. 180:195-198.

  39. Oftung, F., M. Løvik, S. R. Andersen, L. O. Frøholm, and G. Bjune. 1999. A mouse model utilising human transferrin to study protection against Neisseria meningitidis serogroup B induced by outer membrane vesicle vaccination. FEMS Immunol.Med.Microbiol. 26:75-82.

  40. Phyu, S., S. Sornes, T. Mustafa, A. Tadesse, R. Jonsson, and G. Bjune. 1999. Changes in T-lymphocyte subsets in lungs and spleens of mice with slowly progressive primary mycobacterium tuberculosis infection: involvement of unconventional T-cell subsets. Scand.J.Immunol. 50:137-144.

  41. Rasmussen, H., G. Kvarstein, H. Johnsen, H. Dirven, T. Midtvedt, P. Mirtaheri, and T. I. Tønnessen. 1999. Gas supersaturation in the cecal wall of mice due to bacterial CO2 production. J.Appl.Physiol 86:1311-1318.

  42. Rønnestad, A., T. G. Abrahamsen, P. Gaustad, and P. H. Finne. 1999. Antibiotic susceptibility of blood culture isolates after nearly two decades with netilmicin and ampicillin in neonatal septicaemia. APMIS 107:257-262.

  43. Rønnestad, A., T. G. Abrahamsen, P. Gaustad, and P. H. Finne. 1999. C-reactive protein (CRP) response patterns in neonatal septicaemia. APMIS 107:593-600.

  44. Sandven, P. 1999. Detection of fluconazole-resistant Candida strains by a disc diffusion screening test. J.Clin.Microbiol. 37:3856-3859.

  45. Sandven, P. , and J. Lassen. 1999. Importance of selective media for recovery of yeasts from clinical specimens. J.Clin.Microbiol. 37:3731-3732.

  46. Scheel, O., and M. Stormark. 1999. National prevalence survey on hospital infections in Norway. J.Hosp.Infect. 41:331-335.

  47. Skaug, N., E. Lingaas, O. Nielsen, and C. J. Palenik. 1999. Biological monitoring of sterilizers and sterilization failures in Norwegian dental offices in 1985 and 1996. Acta Odontol.Scand. 57:175-180.

  48. Smith, I., A. K. Lehmann, L. Lie, A. Digranes, D. A. Caugant, E. A. Høiby, L. O. Frøholm, and A. Halstensen. 1999. Outbreak of meningococcal disease in western Norway due to a new serogroup C variant of the ET-5 clone: effect of vaccination and selective carriage eradication. Epidemiol.Infect. 123:373-382.

  49. Sommerfelt, M. A. 1999. Retrovirus receptors. J.Gen.Virol. 80 ( Pt 12):3049-3064.

  50. Steinsvik, T. E., I. S. Aaberge, P. I. Gaarder, and M. Løvik. 1999. Interleukin-13 and human immunoglobulin E production in severe combined immunodeficiency mice transplanted with human peripheral blood lymphocytes. Scand.J.Immunol. 49:67-72.

  51. Stray-Pedersen, B., T. Bergan, A. Hafstad, E. Normann, J. Grøgaard, and M. Vangdal. 1999. Vaginal disinfection with chlorhexidine during childbirth. Int.J.Antimicrob.Agents 12:245-251.

  52. Stylianou, E., P. Aukrust, D. Kvale, F. Müller, and S. S. Frøland. 1999. IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin.Exp.Immunol. 116:115-120.

  53. Sundsfjord, A., A. Osei, H. Rosenqvist, M. Van Ghelue, Y. Silsand, H. J. Haga, O. P. Rekvig, and U. Moens. 1999. BK and JC viruses in patients with systemic lupus erythematosus: prevalent and persistent BK viruria, sequence stability of the viral regulatory regions, and nondetectable viremia. J.Infect.Dis. 180:1-9.

  54. Tjøtta, E., O. Hungnes, and B. Grinde. 1999. Mutations designed to alter the stability of a putative RNA duplex in the HIV-1 pol gene. Arch.Virol. 144:2141-2149.

  55. Torfoss, D., P. Aukrust, L. Brinch, O. Mathiesen, G. S. Simonsen, A. K. Axelsen, and P. Gaustad. 1999. Carrier rate of resistant enterococci in a tertiary care hospital in Norway. APMIS 107:545-549.

  56. Viani R., T.J. Gutteberg, J. Lathey, S.A. Spector. 1999. Lactoferrin prevents human immunodeficiency virus type 1 replication in vitro and exhibits synergy when combined with zidovudine. AIDS 13: 1273-1274.

  57. Videm, V., T-E. Mollnes, E. Fosse, B. Mohr, K. Bergh, T-A. Hagve, A.O. Aasen, and J.L. Svennevig. 1999.  Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. J Thorac Cardiovasc Surg 117: 794-802.

  58. Videm, V., T-E. Mollnes, K.  Bergh, E. Fosse, B.  Mohr, T-A. Hagve,  A.O. Aaasen, and J.L. Svennevig. 1999. Heparin-coated cardiopulmonary bypass equipment. II. Mechanisms for reduced complement activation in vivo. J Thorac Cardiovasc Surg 117: 803-809.

  59. Vorland, L. H. 1999. Lactoferrin: a multifunctional glycoprotein. APMIS 107:971-981.

  60. Vorland, L. H., S. A. Osbakk, T. Perstolen, H. Ulvatne, O. Rekdal, J. S. Svendsen, and T. J. Gutteberg. 1999. Interference of the antimicrobial peptide lactoferricin B with the action of various antibiotics against Escherichia coli and Staphylococcus aureus. Scand. J. Infect. Dis. 31:173-177.
  61. Vorland, L. H., H. Ulvatne, J. Andersen, H. H. Haukland, O. Rekdal, J. S. Svendsen, and T. J. Gutteberg. 1999. Antibacterial effects of lactoferricin B. Scand. J. Infect. Dis. 31:179-184.

  62. Vorland, L. H., H. Ulvatne, O. Rekdal, and J. S. Svendsen. 1999. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand. J. Infect. Dis. 31:467-473.

  63. Walberg, M., P. Gaustad, and H. B. Steen. 1999. Uptake kinetics of nucleic acid targeting dyes in S. aureus, E. faecalis and B. cereus: a flow cytometric study. J. Microbiol. Methods 35:167-176.

  64. Ween, O., P. Gaustad, and L. S. Havarstein. 1999. Identification of DNA binding sites for ComE, a key regulator of natural competence in Streptococcus pneumoniae. Mol. Microbiol. 33:817-827.

  65. Witsø, E., L. Persen, K. Loseth, and K. Bergh. 1999. Adsorption and release of antibiotics from morselized cancellous bone. In vitro studies of 8 antibiotics. Acta Orthop.Scand. 70:298-304.